News articles about ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) have been trending somewhat positive recently, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ProShares UltraShort Nasdaq Biotech earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.2040012733667 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of ProShares UltraShort Nasdaq Biotech (BIS) traded up $0.64 during trading hours on Thursday, reaching $22.74. 34,700 shares of the company traded hands, compared to its average volume of 84,967. ProShares UltraShort Nasdaq Biotech has a one year low of $19.50 and a one year high of $35.36.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect ProShares UltraShort Nasdaq Biotech (BIS) Share Price” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at

ProShares UltraShort Nasdaq Biotech Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.

Receive News & Ratings for ProShares UltraShort Nasdaq Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares UltraShort Nasdaq Biotech and related companies with's FREE daily email newsletter.